All In Biotech

Drug Trial Radar · NCT00286897

The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

Last checked: Nov 19, 2026Latest source record: Nov 3, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 702 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

702

Actual

Start

Feb 2006

Primary completion

Jun 2007

Study completion Aug 2007

Sponsor

Lead sponsor
Eisai LimitedEisai
Sponsor type
Industry
First posted
Feb 6, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients will be randomised to receive either placebo or the study drug for a period of 30 weeks, in addition to their standard Parkinsonian medications. During the first 8 weeks, the patient's levodopa doses may be adjusted if necessary by the investigator. For the remainder of the 22 weeks, all medications should be kept stable. Patients will be required to attend the clinic twice during the screening period and then a further 8 times during the treatment period. They will be required to complete home diaries where they will record their motor function. In addition, their doctor will assess their Parkinson's disease during the clinic visits. There will also be blood draws for safety and pharmacokinetic and pharmacogenomics evaluation. Following the treatment and assessment period, they will return to the clinic one month later for follow up.

Conditions

  • Parkinson's Disease

Interventions

  • E2007Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patient diaries: Change from baseline to final efficacy visit in the mean total daily OFF time (hr).

Locations

118 sites in 17 countries. Site status is shown where the registry gives one.

  • University Clinic Innsbruck

    Innsbruck, Austria

  • Department of Neurology

    Vienna, Austria

  • Cliniques Universitaires St-Luc

    Brussels, Belgium

  • C.H.U.de Charleroi

    Charleroi, Belgium

  • U.Z. Antwerpen

    Edegem, Belgium

  • U.Z. Gent

    Ghent, Belgium

  • C.H.R. de la Citadelle

    Liège, Belgium

  • Hopital St-Pierre

    Ottignies, Belgium

  • St-Andries Ziekenhuis

    Tielt, Belgium

  • University Hospital

    Olomouc, Czechia

  • University Hospital

    Ostrava, Czechia

  • Pliklinika Modry Pavilon

    Ostrava, Czechia

  • Nemocnice Pardubice

    Pardubice, Czechia

  • FN Plzen

    Pilsen, Czechia

  • Nemocnice Pisek

    Plsek, Czechia

  • Fakultni nemocnice Kralovske Vinohrady

    Prague, Czechia

  • VFN Praha

    Prague, Czechia

  • Parnu Hospital

    Pärnu, Estonia

  • West Tallinn Central Hospital

    Tallinn, Estonia

  • Tartu University Hospital

    Tartu, Estonia

  • Centre Hospitalier du Pays d'Aix

    Aix-en-Provence, France

  • Service Neurologie

    Bayonne, France

  • CHU Gabrief Montpied

    Clermont-Ferrand, France

  • Contis, Patrick

    Colomiers, France

  • Site not named

    Lille, France

  • Centre de Pharmacologie Clinique et Evaluation Therapeutique

    Marseille, France

  • Site not named

    Nantes, France

  • Hopital de la Pitie Salpetriere

    Paris, France

  • Centre d'Investigation Clinique, Hospital Purpan

    Toulouse, France

  • Kliniken Beelitz GmbH

    Beelitz-Heilstätten, Germany

  • Uni-klinikum Charite, Campus Virchow-klinikum

    Berlin, Germany

  • Site not named

    Bochum, Germany

  • Universitaetsklinikum Carl Gustav Carus

    Dresden, Germany

  • Neurologische Universitatsklinik

    Göttingen, Germany

  • Universitatkrankenhaus Hamburg Eppendorf

    Hamburg, Germany

  • Site not named

    Hanau, Germany

  • Site not named

    Hanover, Germany

  • Paracelsus-Elena-Klinik

    Kassel, Germany

  • Gertrudis-Klinik, Parkinson Klinik

    Leun-Biskirchen, Germany

  • Universitatsklinik Lubeck Klinik fur Neurologie Ratzeburger Allee 160 D-23538 Lubeck

    Lübeck, Germany

Showing 40 of 118 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.